Evolus (EOLS) currently reports a profit margin of -10.85% as of June 2026. That compares with -22.42% in the prior-year period — up 51.6% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Evolus's profit margin history and peer comparisons.

Evolus's profit margin increased from -22.42% to -10.85% — a 51.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Evolus's profit margin of -10.85% is lower than the Healthcare sector average of 13.76%. That is roughly 178.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Evolus's current -10.85% should be judged against Healthcare norms (sector average: 13.76%) and against EOLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -10.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Evolus, and consider following EOLS for alerts when major investors trade the stock.